Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial.
Gerald Chodak
Consultant or Advisory Role - Dendreon
Stock Ownership - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
Paul F. Schellhammer
Honoraria - Dendreon
James Boyd Whitmore
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Philip W. Kantoff
Consultant or Advisory Role - Dendreon